We are investigating possible Andexxa blood clot drug injury lawsuits for patients who developed a pulmonary embolism (PE) or deep vein thrombosis (DVT), or the families of those who died while using Andexxa.
As background, here are our earlier posts:
- “Andexxa Blood Clots and Clotting-Related Deaths: FDA November 2024” (1/22/2024)
- “Andexxa Blood Clot Cases Before Any AstraZeneca Drug Recall” (1/6/2025)
According to this December 12, 2025, MedPage Today news report, “Anticoagulant Reversal Drug Pulled From U.S. Market“, we learned that Andexxa will be withdrawn from the US market next week, on December 22, 2025.
The pharmaceutical company responsible for Andexxa, AstraZeneca, asserts that this Andexxa recall has to do with “commercial reasons”. However, that December 2025 MedPage Today article, as we had previously, points out Andexxa blood clots that have been associated with Andexxa use:
Safety concerns arose as early as 2016’s ANNEXA-4 initial study presentation, however, when outside observers noted a signal of excess thrombotic events among the study’s [Andessa (andexanet)] users. The clotting issue became more apparent with ANNEXA-I showing more thrombotic events (14.6% vs 6.9%) and more thrombosis-related deaths (2.5% vs 0.9%) comparing [Andessa (andexanet)] versus usual care with a prothrombin complex concentrate (PCC).
Even before this December 2025 Andexxa recall in the US, we had been looking into possible Andexxa blood clot drug injury lawsuits for patients who developed a pulmonary embolism (PE) or deep vein thrombosis (DVT), causing them to be hospitalized or resulting in their death.
For those people, we encourage you to submit an Andexxa Blood Clots Case Evaluation Form online – it is free, confidential, and there is no obligation.
[Read the article in full at Drug Injury Watch]Andexxa
Free Case Evaluation
Strictly Confidential, No Obligation